These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

760 related articles for article (PubMed ID: 15883638)

  • 21. Two doses of pamidronate in infants with osteogenesis imperfecta.
    Senthilnathan S; Walker E; Bishop NJ
    Arch Dis Child; 2008 May; 93(5):398-400. PubMed ID: 18089634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases.
    Munns CF; Rauch F; Ward L; Glorieux FH
    J Bone Miner Res; 2004 Oct; 19(10):1742-5. PubMed ID: 15355570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experience with bisphosphonates in osteogenesis imperfecta.
    Glorieux FH
    Pediatrics; 2007 Mar; 119 Suppl 2():S163-5. PubMed ID: 17332237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response.
    Zacharin M; Bateman J
    J Pediatr Endocrinol Metab; 2002 Feb; 15(2):163-74. PubMed ID: 11874181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteogenesis imperfecta, current and future medical treatment.
    Rauch F; Glorieux FH
    Am J Med Genet C Semin Med Genet; 2005 Nov; 139C(1):31-7. PubMed ID: 16278881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome.
    Munns CF; Rauch F; Travers R; Glorieux FH
    J Bone Miner Res; 2005 Jul; 20(7):1235-43. PubMed ID: 15940378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta.
    Shapiro JR; McCarthy EF; Rossiter K; Ernest K; Gelman R; Fedarko N; Santiago HT; Bober M
    Calcif Tissue Int; 2003 Feb; 72(2):103-12. PubMed ID: 12457260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation.
    Rauch F; Munns C; Land C; Glorieux FH
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1268-74. PubMed ID: 16434452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy.
    Rauch F; Plotkin H; Zeitlin L; Glorieux FH
    J Bone Miner Res; 2003 Apr; 18(4):610-4. PubMed ID: 12674321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta.
    Weber M; Roschger P; Fratzl-Zelman N; Schöberl T; Rauch F; Glorieux FH; Fratzl P; Klaushofer K
    Bone; 2006 Sep; 39(3):616-22. PubMed ID: 16644299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
    Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
    J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate.
    Cheung MS; Glorieux FH; Rauch F
    J Bone Miner Res; 2009 Apr; 24(4):669-74. PubMed ID: 19063679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV.
    Zeitlin L; Rauch F; Plotkin H; Glorieux FH
    Pediatrics; 2003 May; 111(5 Pt 1):1030-6. PubMed ID: 12728084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone densitometry in pediatric patients treated with pamidronate.
    Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
    Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
    Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
    Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age.
    Alcausin MB; Briody J; Pacey V; Ault J; McQuade M; Bridge C; Engelbert RH; Sillence DO; Munns CF
    Horm Res Paediatr; 2013; 79(6):333-40. PubMed ID: 23735642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.
    Poyrazoglu S; Gunoz H; Darendeliler F; Bas F; Tutunculer F; Eryilmaz SK; Bundak R; Saka N
    J Pediatr Orthop; 2008 Jun; 28(4):483-7. PubMed ID: 18520289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
    Atta I; Iqbal F; Lone SW; Ibrahim M; Khan YN; Raza J
    J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy.
    Arikoski P; Silverwood B; Tillmann V; Bishop NJ
    Bone; 2004 Mar; 34(3):539-46. PubMed ID: 15003801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.